MK-777 Acetamoren

Description

What is MK-777 Acetamoren?

MK-777 is a non-peptide compound under early-stage laboratory investigation as a potential ghrelin receptor (GHS-R1a) ligand within the spiropiperidine chemical family. Originally developed as part of the growth hormone secretagogue research program, this molecule shares core structural features with the characterized compound ibutamoren (MK-677) but incorporates an acetyl functional group modification that distinguishes its chemical identity. The compound is currently supplied for in vitro receptor binding studies, structure-activity relationship investigations, and analytical method development in preclinical research laboratories examining non-peptide ghrelin receptor pharmacology.

CRITICAL RESEARCH LIMITATION: As of 2026, MK-777 has not been the subject of peer-reviewed clinical or preclinical publication. All investigational applications discussed herein are based on structural analogy to MK-677 and the known pharmacology of the spiropiperidine GHS-R1a agonist chemical class. Any receptor-affinity, half-life, or biological-effect claims are not supported by published peer-reviewed research specific to MK-777.

MK-777 is not a selective androgen receptor modulator (SARM). Despite category placement in some vendor catalogs, MK-777 is a ghrelin receptor ligand under investigation, not an androgen receptor modulator. It is not approved by the FDA for human or veterinary use and is intended strictly for laboratory research purposes.

Chemical Properties

Property	Detail
Product Type	Growth Hormone Secretagogue Receptor Ligand
Product Name	MK-777 (Acetamoren)
Format	Available in liquid, tablet, and capsule forms
Application	Scientific / Research Use Only
CAS	950841-87-9
Molecular Weight	570.7 g/mol
Chemical Formula	C₂₉H₃₈N₄O₆S
PubChem CID	Not available
IUPAC Name	Not available (compound not listed in PubChem database)
Synonyms	Acetamoren, MK777, MK 777
Physical Form	Liquid solution (30 mL bottle, 1,000 mg total, 33 mg/mL concentration); Tablet form (20 mg per tablet, available as 27-tablet supply [540 mg total] or 54-tablet supply [1,080 mg total]); Capsule form (20 mg per capsule, 50-capsule supply [1,000 mg total])
Solubility	Soluble in DMSO; limited aqueous solubility
Storage	Tablet / Capsule: Room temperature  Liquid: Refrigerated (2°C–8°C), tightly sealed, protected from light, heat, and moisture.
Classification	Research Use Only (RUO)

Format note: MK-777 is supplied in three research formats optimized for different experimental protocols. The liquid formulation provides precise volumetric dosing for in vitro assays. Tablet and capsule forms enable standardized unit dosing for preclinical animal research models requiring oral administration routes.

How Does MK-777 Acetamoren Work?

Potential Metabolic Pathway Effects Based on Structural Analogy

Based on documented pharmacology of MK-677 in experimental obesity models, structurally related compounds may potentially influence metabolic parameters. Research on MK-677 has shown increased growth hormone secretion, fat-free mass, and energy expenditure in obese subjects through GHS-R1a activation. Whether MK-777 demonstrates similar metabolic effects remains unknown without experimental investigation.

Potential Ghrelin Receptor Binding Interactions

MK-777 is under investigation in in vitro receptor binding assays as a non-peptide ligand at the growth hormone secretagogue receptor (GHS-R1a). Based on structural similarity to MK-677, which has been characterized as a nonpeptidyl growth hormone secretagogue in preclinical receptor studies, MK-777 may potentially demonstrate binding affinity for this G protein-coupled receptor in comparative pharmacology investigations. The spiropiperidine core structure, shared with MK-677, suggests potential receptor interaction capabilities, though receptor affinity, selectivity, functional efficacy, and downstream signaling effects remain completely uncharacterized in published literature for MK-777.

Hypothetical Growth Hormone Secretagogue Pathway Modulation

If MK-777 demonstrates functional GHS-R1a agonist activity comparable to its structural analog MK-677, it may potentially be investigated for growth hormone release mechanisms in isolated pituitary cell preparations. Preclinical research on MK-677 has documented stimulation of the growth hormone-insulin-like growth factor I axis by daily oral administration, representing receptor-mediated activation of the somatotropic axis. These documented effects of MK-677 provide context for hypothetical investigational directions with structurally related compounds, though no data confirms MK-777 shares these properties.

Potential Sleep Architecture Modulation

Ghrelin receptor agonists in the spiropiperidine class have been investigated for effects on sleep parameters. Studies of MK-677 have documented improvement in sleep quality through growth hormone secretagogue receptor activation in experimental research settings. If MK-777 demonstrates functional GHS-R1a activity, similar investigational applications may be relevant.

Comparative Structure-Activity Relationship Research Context

MK-777 serves as a reference compound within the non-peptide spiropiperidine GHS-R1a agonist family for structure-activity relationship investigation and binding-kinetics research in cell-free and cell-culture assay systems. Comparative analysis against characterized compounds provides context for pharmacological evaluation.

What are the Potential Research Applications of MK-777 Acetamoren?

CRITICAL NOTICE: No peer-reviewed preclinical or clinical data exists specifically for MK-777 as of 2026. The following research applications represent potential investigational areas based on structural similarity to MK-677, not established uses. Researchers should treat MK-777 as an uncharacterized chemical entity requiring de novo pharmacological evaluation.

Based on structural analogy to the spiropiperidine GHS-R1a agonist class, MK-777 may be investigated for the following research applications. No data confirms biological activity for MK-777.

Structural Characterization:

– Molecular identity verification by HPLC-MS in analytical method development

– Nuclear magnetic resonance characterization of acetyl group substitution effects

Receptor Pharmacology:

– GHS-R1a receptor binding kinetics in cell-free assay systems

– Competitive displacement versus characterized reference compounds (MK-677, ibutamoren)

– Dose-response characterization in transfected cell lines

Comparative Pharmacology:

– Structure-activity relationship analysis within the spiropiperidine series

– Receptor selectivity profiling comparing GHS-R1a vs other GPCR targets

 

If functional GHS-R1a activity is demonstrated in preliminary assays, hypothetical investigational areas based on documented MK-677 research may include growth hormone secretion mechanism studies, investigation of effects on body composition and clinical outcomes in experimental aging models, and neuroendocrine pathway characterization.

What are the Potential Side Effects of MK-777 Acetamoren?

SAFETY DATA NOTICE: No safety data, toxicological characterization, or adverse effect profile has been established for MK-777. The following represents documented observations from preclinical and clinical research on the structurally related compound MK-677, not MK-777 itself.

Researchers working with structurally related GHS-R1a agonists have noted:

• No human safety data exists for MK-777 specifically
• No animal toxicity data exists for MK-777 specifically
• Long-term or chronic toxicity data do not exist for MK-777
• Extrapolation from MK-677 data is not scientifically validated for MK-777
• MK-777 must be treated as a compound with unknown toxicological profile

Risk & Handling

MK-777 Acetamoren is an uncharacterized synthetic compound under early-stage investigation.

Risk Tier: HIGH

This rating reflects the absence of toxicological characterization data, unknown receptor affinity and selectivity profile for MK-777 specifically, elevated regulatory exposure associated with GHS-R1a pathway compounds, and the precautionary principle appropriate for uncharacterized synthetic compounds entering early-stage analytical and receptor pharmacology investigation. Researchers must observe the following precautions at all times. 

Handling Precautions: MK-777 should be handled exclusively in a controlled laboratory environment by trained personnel. Use appropriate PPE at all times. Avoid direct skin and eye contact. Avoid inhalation of powder. For liquid formulations, handle with chemical-resistant gloves and avoid accidental ingestion or skin contact.

Exposure Risks: No human safety data has been established. No animal safety data has been established. Toxicological profile is completely unknown.

Regulatory Risk: Growth hormone is controlled under the Anti-Drug Abuse Act of 1988. Compounds that may interact with growth hormone secretagogue pathways carry elevated regulatory exposure. Unauthorized human use or distribution may violate federal law.

Storage: 

Tablet / Capsule:Storage: Store in a tightly sealed container at room temperature. Protect from light, heat, and moisture.

Liquid:Storage: Store as directed for the formulation, typically refrigerated (2°C–8°C). Protect from light, heat, and moisture. Keep tightly sealed.

FAQs

Is MK-777 a SARM?

No. MK-777 is a potential ghrelin receptor ligand under investigation, not a selective androgen receptor modulator. It shares no structural or mechanistic relationship with SARMs despite occasional miscategorization in vendor catalogs.

What is the relationship between MK-777 and MK-677?

MK-777 (Acetamoren) is structurally related to MK-677 (Ibutamoren) within the spiropiperidine GHS-R1a agonist chemical family. However, MK-777 is a chemically distinct compound with a different molecular formula (C₂₉H₃₈N₄O₆S vs. C₂₇H₃₆N₄O₅S for MK-677) and has not been characterized in published peer-reviewed research as of 2026.

Is there published research on MK-777?

No. As of 2026, no peer-reviewed publications specific to MK-777 (Acetamoren) are available. All mechanistic discussion and potential research applications are based on structural analogy to MK-677 and should be considered hypothetical until experimental data is generated.

Is MK-777 Acetamoren approved for human or veterinary use?

No. MK-777 is not FDA-approved and is exclusively intended for laboratory research purposes. Review the Terms and Conditions before ordering.

What forms of MK-777 are available from RCDbio?

RCDbio supplies MK-777 in three research formats: liquid solution (30 mL, 33 mg/mL), tablet form (20 mg tablets in 27 or 54 count), and capsule form (20 mg capsules, 50 count). Format selection depends on experimental protocol requirements.

References

Research Transparency Note: The following references relate to the parent compound class (MK-677/ibutamoren) and the ghrelin receptor pharmacology field that provides context for MK-777 research. No peer-reviewed publications specific to MK-777 are available as of 2026.

• Smith, R.G., Cheng, K., Schoen, W.R., Patchett, A.A., Hickey, G.J., Wyvratt, M.J., Fisher, M.H., Nargund, R.P., Stark, P., Crosby, S.R., & Et al. (1993). A nonpeptidyl growth hormone secretagogue. Science, 260(5114), 1640–1643. https://doi.org/10.1126/science.8503008
• Chapman, I.M., Bach, M.A., Van Cauter, E., Farmer, M., Krupa, D., Taylor, A.M., Schilling, L.M., Cole, K.Y., Skiles, E.H., Pezzoli, S.S., Hartman, M.L., Veldhuis, J.D., Gormley, G.J., & Thorner, M.O. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism, 81(12), 4249–4257. https://doi.org/10.1210/jcem.81.12.8954023
• Svensson, J., Lönn, L., Jansson, J.O., Murphy, G., Wyss, D., Krupa, D., Cerchio, K., Polvino, W., Gertz, B., Boseaus, I., Sjöström, L., & Bengtsson, B.Å. (1998). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism, 83(2), 362–369. https://doi.org/10.1210/jcem.83.2.4539
• Copinschi, G., Leproult, R., Van Onderbergen, A., Caufriez, A., Cole, K.Y., Schilling, L.M., Mendel, C.M., De Lepeleire, I., Bolognese, J.A., & Van Cauter, E. (1997). Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 66(4), 278–286. https://doi.org/10.1159/000127249
• Nass, R., Pezzoli, S.S., Oliveri, M.C., Patrie, J.T., Harrell, F.E., Jr, Clasey, J.L., Heymsfield, S.B., Bach, M.A., Vance, M.L., & Thorner, M.O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine, 149(9), 601–611. https://doi.org/10.7326/0003-4819-149-9-200811040-00003

 

Disclaimer

MK-777 Acetamoren is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co